Table 2 Association of the ITGB3 polymorphism with ovarian cancer risk and no association with breast cancer risk.
| Genotype/allele | Ovarian cancer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n = 146) n (%) | Controls (n = 280) n (%) | ORcrude* (95% CI) | p Value | Cases (n = 85) n (%) | Controls (n = 215) n (%) | ORadj† (95% CI) | p Value | ORclustered‡ (95% CI) | p Value | |
| ITGB3_Leu33Pro | ||||||||||
| Leu/Leu | 96 (66) | 224 (80) | 1.00 (reference) | 57 (67) | 172 (80) | 1.00 (reference) | 1.00 (reference) | |||
| Leu/Pro+Pro/Pro | 50 (34) | 56 (20) | 2.08 (1.33 to 3.27) | 0.002 | 28 (33) | 43 (20) | 2.51 (1.3 to 4.84) | 0.006 | 1.97 (1.53 to 2.53) | p<0.001 |
| Pro | 57 (19) | 61 (11) | 29 (17) | 47 (11) | ||||||
| Genotype/allele | Breast cancer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n = 319) n (%) | Controls (n = 290) n (%) | ORcrude* (95% CI) | p Value | Cases (n = 232) n (%) | Controls (n = 225) n (%) | ORadj† (95% CI) | p Value | ORclustered‡ (95% CI) | p Value | |
| ITGB3_Leu33Pro | ||||||||||
| Leu/Leu | 249 (78) | 233 (80) | 1.00 (reference) | 184 (79) | 181 (80) | 1.00 (reference) | 1.00 (reference) | |||
| Leu/Pro+Pro/Pro | 70 (22) | 57 (20) | 1.15 (0.77 to 1.70) | 0.62 | 48 (21) | 44 (20) | 1.12 (0.69 to 1.82) | 0.63 | 1.14 (0.82 to 1.59) | 0.43 |
| Pro | 76 (12) | 62 (11) | 49 (11) | 48 (11) | ||||||
*ORcrude, crude odds ratio.
†ORadj, odds ratio adjusted for year of birth, age of first live birth, age at menarche, body mass index, parity, breastfeeding, oral contraceptive use, smoking and BRCA1 mutation.
‡ORclustered, odds ratio on correction for family cluster.